<DOC>
	<DOCNO>NCT00489190</DOCNO>
	<brief_summary>To collect effectiveness safety data treatment Apidra glulisine ( HMR1964 ) mean subcutaneous injection patient Diabetes Mellitus 1st type 12 weeks-active phase .</brief_summary>
	<brief_title>APIDRA Registration Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<criteria>Diabetes Mellitus 1st type , НbA1c level range ≥ 6,5 &lt; =11 % , receive regimen multiple injection insulin one year . Active proliferative diabetic retinopathy connect focal panretinal photocoagulation vitrectomy carry within 6 month visit 1 , unstable ( quickly progressive ) form retinopathy , may need surgical intervention ( include laser photocoagulation ) study Diabetes Mellitus 2nd type Patients transmit pancreatectomy Patients transmit transplantation pancreas islet cell Probable therapy mean product approve study minute study Anamnestic indication convulsive disorder Allergic reaction insulin filler preparation Apidra ( glulisine ) Clinical serious disease cardiovascular system , liver , nervous system , endocrine system , oncologic disease serious system disease , complicate keep minute interpretation study result , , investigator 's opinion , impede safe participation patient study Drug addiction alcoholism Disturbance liver function confirm increase ALT AST activity level twice high upper standard limit ( indication may single ) Disturbance function kidney confirm level creatinine serum 177 mµmol/l visit 1 ( indication may single ) Pregnancy breastfeed The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>